Patents Assigned to Rational Drug Design Laboratories
-
Patent number: 7465748Abstract: There is provided a pharmaceutical drug, particularly a novel compound useful for prophylaxis or a therapeutic treatment of various diseases involving infections with viruses of the herpesvirus family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. An N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative, of which phenyl group is substituted at position 4 with a specific 5- or 6-membered heteroaryl group, and a salt thereof have an effective anti-virus activity, and the oral administration thereof at a low dose enabled the therapeutic treatment of the above diseases.Type: GrantFiled: August 5, 2004Date of Patent: December 16, 2008Assignees: Astellas Pharma Inc., Rational Drug Design LaboratoriesInventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Tomoaki Kawano, Akio Kamikawa, Hiroshi Suzuki, Kenji Sudo
-
Patent number: 6949543Abstract: The invention relates to a novel amide derivative which is an N-({[4-(substituted thiazol-4-yl)phenyl]carbamoyl}methyl)amide derivative having a characteristic in that an aryl or heteroaryl group as an aromatic ring group is directly substituted on the N atom of amido group. Since said amide derivative has excellent anti-herpesvirus action, it is useful as medicaments and antiviral agents, particularly as preventive or therapeutic agents for various diseases accompanied by Herpesviridae virus infections, illustratively, varicella (chickenpox) accompanied by varicella zoster virus infection, shingles accompanied by the recurrent infection of latent varicella zoster virus, labial herpes and herpes encephalitis accompanied by HSV-1 infection, genital herpes accompanied by HSV-2 and the like various herpesvirus infections.Type: GrantFiled: November 8, 2001Date of Patent: September 27, 2005Assignees: Yamanouchi Pharmaceutical Co., Ltd., Rational Drug Design LaboratoriesInventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Yoji Miyazaki, Hiroshi Suzuki, Eiichi Nakai, Shunji Kageyama
-
Patent number: 6903125Abstract: A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. N-{2-[(4-Substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative where the phenyl group is substituted at position 4 with a specific five-membered or 6-membered heteroaryl group, has such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases.Type: GrantFiled: August 6, 2004Date of Patent: June 7, 2005Assignees: Yamanouchi Pharmaceutical Co., Ltd., Rational Drug Design LaboratoriesInventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Tomoaki Kawano, Akio Kamikawa, Hiroshi Suzuki, Kenji Sudo
-
Patent number: 5948916Abstract: Novel arylthiadiazole derivatives and salts thereof useful for preventing and treating human viral infection and a novel virucide which contains the arylthiadiazole derivative or a salt thereof are provided. N,N-dimethyl ?3-(3-(amino-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl! carbamate or its salt, and virucide containing the same as an effective component.Type: GrantFiled: June 9, 1997Date of Patent: September 7, 1999Assignee: Rational Drug Design LaboratoriesInventors: Katsushi Ijichi, Shiro Shigeta, Masanori Baba, Masatoshi Fujiwara, Tomoyuki Yokota, Hiromitsu Takayama, Shin-ichiro Sakai, Yasuaki Hanasaki, Teruhiko Ide, Hiroyuki Watanabe, Kimio Katsuura
-
Patent number: 5837463Abstract: An objective of this invention is to clarify the sequence of the 3'-end site of HCV genome and to provide a new process for detecting HCV.A new sequence with a highly conserved 3'-end site of the HCV genome has been found. Using the said sequences, new process for detecting HCV, a process for inhibiting proliferation of HCV, etc. have been provided.Type: GrantFiled: October 11, 1996Date of Patent: November 17, 1998Assignees: Rational Drug Design Laboratories, National Cancer CenterInventors: Torahiko Tanaka, Nobuyuki Katoh, Kunitada Shimotohno
-
Patent number: 5698580Abstract: Antiviral agents comprising, as an active ingredient, a 1,4-dihydro-2,3-benzodithiin derivative of the formula ##STR1## wherein each symbol is as defined in the Specification, or a pharmacologically acceptable salt thereof. The antiviral agents of the present invention have superior antiviral activity and are effective for the preventive and therapeutic treatment of viral diseases caused typically by RS virus.Type: GrantFiled: December 16, 1996Date of Patent: December 16, 1997Assignee: Rational Drug Design LaboratoriesInventors: Tsuyoshi Kajiyashiki, Ryu Sato, Tomoyuki Yokota, Kenji Sudo, Wataru Watanabe, Shiro Shigeta